Genomic Health, Inc.

Robert J Pelham

Tara Maddala

Michael R Crager

Mark Lee

Diana Cherbavaz

Steven Shak

Dejan Knezevic

William F Novotny

Carl L Millward

Audrey Goddard

Joffre B Baker

Michael C Kiefer

Wayne Cowens

Steve Shak

Frederick L Baehner

John Morlan

Kunbin Qu

Francois Collin

Mei-Lan Liu

James C Stephans

Dominick V Sinicropi

The present invention provides algorithm-based molecular assays that involve measurement of expression levels of genes, or their co-expressed genes, from a biological sample obtained from a prostate cancer patient. The genes may be grouped into functional gene subsets for calculating a quantitative score useful to predict a likelihood of a clinical outcome for a prostate cancer patient.

Gene expression profile algorithm and test for determining prognosis of prostate cancer

The present disclosure includes assays that involve measurement of expression levels of prognostic biomarkers, or co-expressed biomarkers, from a biological sample obtained from a prostate cancer patient, and analysis of the measured expression levels to provide information concerning the likely prognosis for the patient, and likelihood that the patient will have a recurrence of prostate cancer, or to classify the tumor by likelihood of clinical outcome or TMPRSS2 fusion status.

Method for using gene expression to determine prognosis of prostate cancer

Growing community of inventors

Belmont, CA, United States of America

Robert J Pelham